Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Depreciation and Depletion (2020 - 2022)

Protagonist Therapeutics (PTGX) has disclosed Depreciation and Depletion for 3 consecutive years, with $254000.0 as the latest value for Q4 2022.

  • Quarterly Depreciation and Depletion rose 8.09% to $254000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2022, up 26.94% year-over-year, with the annual reading at $1.2 million for FY2025, 37.02% up from the prior year.
  • Depreciation and Depletion hit $254000.0 in Q4 2022 for Protagonist Therapeutics, down from $270000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $270000.0 in Q3 2022 to a low of $180000.0 in Q1 2021.
  • Historically, Depreciation and Depletion has averaged $225888.9 across 3 years, with a median of $235000.0 in 2021.
  • Biggest YoY gain for Depreciation and Depletion was 40.0% in 2022; the steepest drop was 8.09% in 2022.
  • Year by year, Depreciation and Depletion stood at $188000.0 in 2020, then rose by 25.0% to $235000.0 in 2021, then rose by 8.09% to $254000.0 in 2022.
  • Business Quant data shows Depreciation and Depletion for PTGX at $254000.0 in Q4 2022, $270000.0 in Q3 2022, and $259000.0 in Q2 2022.